



Emerging Viruses and Antiviral Drugs

Guest Editors:

Dr. Veronica Soloveva

Department of Quantitative
Biosciences, Merck, Boston, MA,
USA

Dr. Miguel A. Martín-Acebes

Department of Biotechnology,
Instituto Nacional de
Investigación y Tecnología
Agraria y Alimentaria (INIA), 28040
Madrid, Spain

Dr. Sina Bavari

CSO, Co-Founder of Healion Bio,
Frederick, MD, USA

Deadline for manuscript
submissions:

closed (31 March 2023)

Message from the Guest Editors

Emerging viruses are a very broad category that includes not only newly discovered viruses but also re-emerging variants of known viruses. These viruses continue to cause mass disruption by creating constant threat to public health. In the last 20 years, we have observed a variety of viral outbreaks, such as severe acute respiratory symptom (SARS), H1N1 influenza, Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), Rift Valley fever, Crimean Congo hemorrhagic fever, Nipah and Hendra viruses, severe fever with thrombocytopenia syndrome virus (SFTSV), yellow fever virus (YFV), Zika virus, and the ongoing SARS-CoV-2. The globalization of the economies and quick-paced traveling patterns of human populations, combined with climate change, are creating ample opportunities for mass spread of viral infections.

This Special Issue, “Emerging Viruses and Antiviral Drugs”, focuses on various antiviral approaches to manage emerging and re-emerging viruses and will include antiviral drug discovery, discovery of the mechanism of actions, new targets, and upcoming and established technologies used for discovery and development of antiviral drugs.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular
Systems Biology, UFZ-Helmholtz
Centre for Environmental
Research, 04318 Leipzig,
Germany

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*Microbiology (medical)*)

Contact Us

Microorganisms Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/microorganisms
microorganisms@mdpi.com
X@Micro_MDPI